• Lantheus Holdings recently reported that an image generated with its investigational LNTH-2513 (18F-GP1) PET/CT won SNMMI’s 2026 “Image of the Year,” based on an investigator-initiated trial showing high diagnostic accuracy for detecting acute lower-extremity DVT and identifying concomitant pulmonary embolism with no drug-related adverse events.
• Beyond DVT detection, the trial highlighted LNTH-2513’s ability to visualize active thrombi throughout the body, including unexpected clots linked to an underlying autoimmune clotting disorder, underscoring its potential value in complex thrombotic disease assessment.
• We’ll now examine how this award-winning thrombus-specific PET/CT data for LNTH-2513 could influence Lantheus’s investment narrative built around radiodiagnostic expansion.

AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Lantheus Holdings Investment Narrative Recap

To own Lantheus, you need to believe its radiodiagnostic portfolio can broaden beyond PYLARIFY, reducing concentration risk while supporting steady earnings growth. The Image of the Year recognition for LNTH-2513 reinforces that pipeline story but does not change the fact that near term catalysts still hinge on launches like the new PYLARIFY formulation and PNT2003, while the biggest risk remains pricing and share pressure in PSMA PET and reimbursement resets across the portfolio.

Among recent announcements, the tentative FDA approval of PNT2003, a generic version of Lutathera, stands out as the most relevant complement to LNTH-2513. Together, they highlight Lantheus’s push to deepen its presence in both diagnostic and therapeutic radiopharmaceuticals, which could gradually reduce dependence on PYLARIFY and provide additional levers if pricing or volume trends in the core prostate cancer imaging business become more challenging.

Yet even as LNTH-2513 adds to the story, investors should be aware that intensifying pricing pressure and reimbursement shifts could still...

Lantheus Holdings' narrative projects $1.9 billion revenue and $431.2 million earnings by 2029. This requires 7.4% yearly revenue growth and about a $152 million earnings increase from $279.0 million today.

Uncover how Lantheus Holdings' forecasts yield a $104.08 fair value, a 4% upside to its current price.

Exploring Other Perspectives

While consensus focuses on pricing and PYLARIFY risk, the most optimistic analysts saw LNTH reaching about US$2.2 billion in revenue and US$779.6 million in earnings, so Image of the Year level data on LNTH-2513 could eventually shift how you weigh pipeline strength against concentrated product risk.

Explore 6 other fair value estimates on Lantheus Holdings - why the stock might be worth 24% less than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Lantheus Holdings research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Lantheus Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Lantheus Holdings' overall financial health at a glance.

Searching For A Fresh Perspective?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Find 47 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.